Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2016

Open Access 01-07-2016 | Epidemiology

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

Authors: Shusma C. Doebar, Esther C. van den Broek, Linetta B. Koppert, Agnes Jager, Margreet. H. A. Baaijens, Inge-Marie A. M. Obdeijn, Carolien H. M. van Deurzen

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Login to get access

Abstract

Ductal carcinoma in situ (DCIS) is a precursor of invasive breast carcinoma (IBC). The DCIS component is often more extensive than the invasive component, which affects local control. The aim of our study was to analyze features of DCIS within different IBC subtypes, which may contribute to the optimization of personalized approaches for patients with IBC. Patients with IBC reported according to the synoptic reporting module in the Netherlands between 2009 and 2015 were included. Data extraction included characteristics of the invasive component and, if present, several features of the DCIS component. Resection margin status analyses were restricted to patients undergoing breast-conserving surgery (BCS). Differences between subtypes were tested by a Chi-square test, spearman’s Rho test or a one-way ANOVA test. Overall, 36.937 cases of IBC were included. About half of the IBCs (n = 16.014; 43.4 %) were associated with DCIS. Her2+ IBC (irrespective of ER status) was associated with a higher prevalence of adjacent DCIS, a larger extent of DCIS and a higher rate of irradicality of the DCIS component as compared to ER+/Her2− and triple-negative subtypes (P < 0.0001 for all variables). The prevalence of DCIS in triple-negative IBC on the other hand was lowest. In this large population-based cohort study, we showed significant differences between the prevalence and extent of DCIS according to IBC subtypes, which is also reflected in the resection margin status in patients treated with BCS. Our data provide important information regarding the optimization of local therapy according to IBC subtypes.
Literature
1.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed
2.
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874CrossRefPubMedPubMedCentral
3.
Louwman MW, Vriezen M, van Beek MW et al (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121:127–135CrossRefPubMed
4.
Nielsen TO, Perou CM (2015) CCR 20th Anniversary Commentary: the Development of Breast Cancer Molecular Subtyping. Clin Cancer Res 21:1779–1781CrossRefPubMed
5.
Ng CK, Schultheis AM, Bidard FC, Wiegelt B, Reis-Filho JS et al (2015) Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst 107:djv015CrossRefPubMed
6.
7.
Guedj M, Marisa L, de Reynies A et al (2012) A refined molecular taxonomy of breast cancer. Oncogene 31:1196–1206CrossRefPubMed
8.
Van Steenbergen LN, Voogd AC, Roukema JA et al (2009) Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res Treat 115:181–183CrossRefPubMed
9.
Louwman WJ, Voogd AC, van Dijck JA et al (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19:97–106CrossRefPubMed
10.
Steinman S, Wang J, Bourne P, Yang Q, Tang P (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37:127–134PubMed
11.
Park K, Han S, Kim H, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:702–707CrossRefPubMed
12.
Steinman S, Wang J, Bourne P, Kim J, Shin E (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37:127–134PubMed
13.
Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ (2008) Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 98:137–142CrossRefPubMed
14.
Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 104:120–127CrossRefPubMed
15.
Zhou W, Jirström K, Amini RM et al (2013) Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 13:512CrossRefPubMedPubMedCentral
16.
Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67CrossRefPubMedPubMedCentral
17.
Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292CrossRefPubMedPubMedCentral
18.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed
19.
Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedPubMedCentral
20.
Kurbel S (2013) In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol 4:1–7CrossRef
21.
Van Steenbergen LN, Voogd AC, Roukema JA et al (2014) Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast 23:63–68CrossRefPubMed
22.
Vidali C, Caffo O, Aristei C et al (2012) Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. Radiat Oncol 7:177CrossRefPubMedPubMedCentral
23.
Rakovitch E, Nofech-Mozes S, Hanna W et al (2012) HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 13(106):1160–1165CrossRef
24.
Donker M, Litiere S, Werutsky G et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054CrossRefPubMed
25.
Han K, Nofech-Mozes S, Narod S et al (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. J Clin Oncol 24:183–189CrossRef
26.
Lazzeroni M, Guerrieri-Gonzaga A, Botteri E et al (2013) Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer 108:1593–1601CrossRefPubMedPubMedCentral
27.
Williams KE, Barnes NLP, Cramer A et al (2015) Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 26:1019–1025CrossRefPubMed
28.
Curigliano G, Disalvatore D, Esposito A et al (2015) Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol 26:682–687CrossRefPubMed
29.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691CrossRefPubMed
30.
Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMed
31.
Rezai M, Kellersmann S, Knispel S, Lax H, Kimmig R, Kern P (2015) Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients—predictors of recurrence and survival. Breast 24:384–390CrossRefPubMed
32.
Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMedPubMedCentral
33.
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed
34.
35.
Wolff AC, Hammond ME, Hicks DG et al (2013) American society of clinical oncology; college of American pathologists. recommendations for human epidermal growth factor 2 testing in breast cancer: american society of clinical oncology/college of American pathologists practice guideline update. J Clin Oncol 31:3997–4013CrossRefPubMed
36.
Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223CrossRefPubMedPubMedCentral
37.
Prat A, Cheang MC, Martín M et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203–209CrossRefPubMed
38.
Nuclear dcis: the consensus conference committee (1997) Consensus conference on the classification of ductal carcinoma. Cancer 80:1798–1802CrossRef
39.
40.
Buchholz TA, Somerfield MR, Griggs JJ et al (2014) Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: american Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 32:1502–1506CrossRefPubMed
41.
Jia H, Jia W, Yang Y et al (2014) HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World J Surg Oncol 12:289CrossRefPubMedPubMedCentral
42.
Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 15:593–602CrossRefPubMed
43.
Tot T (2015) Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival. Ann Surg Oncol 22:2532–2539CrossRefPubMed
44.
Vicini FA, Eberlein TJ, Connolly JL et al (1991) The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg 214:200–205CrossRefPubMedPubMedCentral
45.
Greenwood HI, Heller SL, Kim S, Sigmund EE, Shaylor SD, Moy L (2013) Ductal carcinoma in situ of the breasts: review of MR imaging features. Radiographics 33:1569–1588CrossRefPubMed
46.
Yamada T, Mori N, Watanabe M et al (2010) Radiologic-pathologic correlation of ductal carcinoma in situ. Radiographics 30:1183–1198CrossRefPubMed
Metadata
Title
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
Authors
Shusma C. Doebar
Esther C. van den Broek
Linetta B. Koppert
Agnes Jager
Margreet. H. A. Baaijens
Inge-Marie A. M. Obdeijn
Carolien H. M. van Deurzen
Publication date
01-07-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3862-4

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue

Preclinical study

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

Brief Report

Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer

Clinical Trial

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

Epidemiology

The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases

Preclinical study

Aberrant nocturnal cortisol and disease progression in women with breast cancer

Preclinical study

Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits